康方生物宣布Cadonilimab(PD-1/CTLA-4双抗)治疗PD-1耐药肝细胞癌全球注册试验完成首位患者给药

美股速递
Sep 15

康方生物宣布,其PD-1/CTLA-4双特异性抗体药物Cadonilimab治疗PD-1治疗耐药肝细胞癌的全球注册试验已完成首位患者给药,这标志着该项重要临床研究正式启动。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10